Obermatt
See Similar Stocks →

MoonLake Immunotherapeutcs

NAQ:MLTX · KY61559X1045
BiotechnologySmall

360° View

13
Price/Sales1
Price/Earnings51
Price/Book100
Dividend Yield1
Revenue Growth—
Profit Growth10
Capital Growth98
TSR 52w7
Leverage44
Liquidity27
Refinancing44
Combined25
Analyst Opinions26
Pro Holdings67
Opinion Changes20
Market Pulse81

Profile

CountrySwitzerland
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Employees125
Websitemoonlaketx.com
ISINKY61559X1045
Last UpdateApr 2, 2026
Index & Theme
DermatologyInflammationChronic DiseasesPain ManagementRheumatologyImmunology

Description

MoonLake Immunotherapeutics is a clinical stage biotechnology company advancing therapies to address significant unmet needs in inflammatory skin and joint diseases. The company develops SLK in inflammatory diseases in dermatology and rheumatology w…

Analysis

MoonLake Immunotherapeutcs's 360° View rank of 13 places it among the weakest overall — better than 13% of its true peers.

It's growing slowly (38) and reasonably valued (51). On safety it is carrying more balance-sheet risk (32), and the market shows muted sentiment (37). Taken together, its Combined rank of 25 reads as among the weakest overall.

360° rank · history

1007550250
13
2026

All-time high

13

Jun 2026

All-time low

1

Mar 2026

Average rank

7

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
1
—
—
—
Price/Earnings
51
—
—
—
Price/Book
100
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
51
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare MoonLake Immunotherapeutcs with its peers
Newron Pharmaceuticals
SWX:NWRN
15
CountryItaly
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
OKYO Pharma
NAQ:OKYO
40
CountryUK
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Immatics
NAQ:IMTX
31
CountryGermany
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Galapagos
AEX:GLPG
76
CountryBelgium
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
ABIVAX
PAR:ABVX
26
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Innate Pharma
PAR:IPH
54
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →